Vantage logo

Ovid joins the rare epilepsy race

Ovid Therapeutics gets a mid-stage win in Dravet syndrome, but might have a hard time going up against Zogenix’s Fintepla.

Vantage logo

Zogenix hands GW a win

A phase III Lennox-Gastaut trial sees Fintepla meet statistical significance but fail the test of clinical relevance.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.